Details for New Drug Application (NDA): 021866
✉ Email this page to a colleague
The generic ingredient in ABILIFY is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
Summary for 021866
Tradename: | ABILIFY |
Applicant: | Otsuka |
Ingredient: | aripiprazole |
Patents: | 2 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 021866
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAMUSCULAR | Strength | 9.75MG/1.3ML (7.5MG/ML) | ||||
Approval Date: | Sep 20, 2006 | TE: | RLD: | No | |||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Jan 21, 2025 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Patent: | ⤷ Try a Trial | Patent Expiration: | Jan 21, 2025 | Product Flag? | Substance Flag? | Delist Request? | Y |
Expired US Patents for NDA 021866
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Otsuka | ABILIFY | aripiprazole | INJECTABLE;INTRAMUSCULAR | 021866-001 | Sep 20, 2006 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription